You are here: Home: Meet The Professors Vol. 1 2003: Case 6: Select publications

 

Select publications: Treatment of carcinoma of unknown primary origin

Culine S et al. Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site. Cancer 2002;94(3):840-6. Abstract.

Elkordy M et al. A phase II study of weekly paclitaxel (Taxol®) and carboplatin in advanced carcinoma of unknown primary origin. Proc ASCO 2001:Abstract 1603.

Fizazi K et al. Carcinoma of unknown primary (CUP): Are the tyrosine kinase receptors HER- 2, EGF-R, and c-Kit suitable targets for therapy? Proc ASCO 2003;Abstract 3549.

Greco FA et al. Carcinoma of unknown primary site. Cancer 2000;89(12):2655-60. Abstract.

Greco FA et al. Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000;11(2):211-5. Abstract.

Greco FA et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: A Minnie Pearl Cancer Research Network study. J Clin Oncol 2002;20(6):1651-6. Abstract.

Greco FA et al. Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J 2001;7(3):203-12. Abstract.

Guardiola E et al. Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site: A phase II trial. Am J Clin Oncol 2001;24(4):372-5. Abstract.

Hainsworth JD et al. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: A phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest 2001;19(4):335-9. Abstract.

Hainsworth JD, Greco FA. Management of patients with cancer of unknown primary site. Oncology (Huntingt) 2000;14(4):563-74;discussion 574-6, 578-9. Abstract.

Karapetis CS et al. Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site. Med Oncol 2001;18(1):23-32. Abstract.

Macdonald AG et al. A phase II study of mitomycin C, cisplatin and continuous infusion 5- fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site. Br J Cancer 2002;86(8):1238-42. Abstract.

Mahomed R et al. Age as a prognostic factor in metastatic cancer of unknown primary (CUP). Long term follow up results. Proc ASCO 2003;Abstract 3590.

Mukai H et al. A safety and efficacy trial of docetaxel (D) and cisplatin (P) in patients with cancer of unknown primary (CUP). Proc ASCO 2003;Abstract 2597.

Saghatchian M et al. Carcinoma of an unknown primary site: A chemotherapy strategy based on histological differentiation – Results of a prospective study. Ann Oncol 2001;12(4):535-40. Abstract.

Sumi H et al. Treatable subsets in cancer of unknown primary origin. Proc ASCO 2000:Abstract 2279D. Abstract.

Veach SR et al. Cancer of unknown primary, trends in diagnosis and care. Proc ASCO 2003;Abstract 2238.

Voog E et al. Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary. Am J Clin Oncol 2000;23(6):614-6. Abstract.

Table of Contents Top of Page 

 

Home · Search

 
CME Information
Faculty
Editor's Note
 
CASE 1: Disease recurrence and brachial plexopathy during the third trimester of pregnancy
- Select publications
 
CASE 2: Unresectable local recurrence in the pectoralis major after breast-conserving
surgery
- Select publications
 
CASE 3: Pulmonary metastases and mild shortness of breath
- Select publications
 
CASE 4: HER2-positive metastases to the lung and residual local breast cancer after lumpectomy
- Select publications
 
CASE 5: Liver metastases and mild hepatic encephalopathy
- Select publications
 
CASE 6: Ascites and pleural effusion ten years after primary breast cancer
- Select publications
Home · Contact us
Terms of use and general disclaimer